The cost of health care for children and adults with sickle cell disease

被引:304
作者
Kauf, Teresa L. [1 ]
Coates, Thomas D. [2 ]
Liu Huazhi [1 ]
Mody-Patel, Nikita [3 ]
Hartzema, Abraham G. [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, Gainesville, FL 32611 USA
[2] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Ctr Canc & Blood Dis, Los Angeles, CA 90033 USA
[3] Novartis Pharmaceut Inc, Hlth Econ & Outcomes Res, E Hanover, NJ USA
关键词
UNITED-STATES; MANAGED CARE; ANEMIA; HYDROXYUREA; PREVENTION; MORTALITY; ILLNESSES; MEDICAID; LIFE;
D O I
10.1002/ajh.21408
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although sickle cell disease (SCD) is marked by high utilization of medical resources, the full cost of care for patients with SCD, including care not directly related to SCD, is unknown. The purpose of this study was to estimate the total cost of medical care for a population of children and adults with SCD. We used data from individuals diagnosed with SCD enrolled in the Florida Medicaid program during 2001-2005 to estimate total, SCD-related, and non-SCD-related cost per patient-month based on patient age at the time of health care use. Across the 4,294 patient samples, total health care costs generally rose with age, from $892 to $2,562 per patient-month in the 0-9- and 50-64-year age groups, respectively. Average cost per patient-month was $1,389. Overall, 51.8% of care was directly related to SCD, the majority of which (80.5%) was associated with inpatient hospitalizations. Notably, non-SCD-related costs were substantially higher than those reported for the general US population. These results suggest a discounted (3% discount rate) lifetime cost of care averaging $460,151 per patient with SCD. Interventions designed to prevent SCD complications and avoid hospitalizations may reduce the significant economic burden of the disease. Am. J. Hematol. 84:323-327, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:323 / 327
页数:5
相关论文
共 31 条
  • [1] [Anonymous], HLTH US 2006
  • [2] [Anonymous], 1996, Cost-effectiveness in health and medicine
  • [3] Hydroxyurea and sickle cell anemia: effect on quality of life
    Ballas, Samir K.
    Barton, Franca B.
    Waclawiw, Myron A.
    Swerdlow, Paul
    Eckman, James R.
    Pegelow, Charles H.
    Koshy, Mabel
    Barton, Bruce A.
    Bonds, Duane R.
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
  • [4] The cost of epilepsy in the United States: An estimate from population-based clinical and survey data
    Begley, CE
    Famulari, M
    Annegers, JF
    Lairson, DR
    Reynolds, TF
    Coan, S
    Dubinsky, S
    Newmark, ME
    Leibson, C
    So, EL
    Rocca, WA
    [J]. EPILEPSIA, 2000, 41 (03) : 342 - 351
  • [5] The costs of children with sickle cell anemia: Preparing for managed care
    Bilenker, JH
    Weller, WE
    Shaffer, TJ
    Dover, GJ
    Anderson, GF
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1998, 20 (06) : 528 - 533
  • [6] Have Medicaid reimbursements been a credible measure of the cost of pediatric care?
    Broyles, RS
    Tyson, JE
    Swint, JM
    [J]. PEDIATRICS, 1997, 99 (03) : art. no. - e8
  • [7] *BUR LAB STAT, 2008, CONS PRIC IND HOM PA
  • [8] *CDCP, 2008, SICKL CELL DIS
  • [9] Davis H, 1997, PUBLIC HEALTH REP, V112, P40
  • [10] Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States
    Delea, Thomas E.
    Hagiwara, May
    Thomas, Simu K.
    Baladi, Jean-Francois
    Phatak, Pradyumna D.
    Coates, Thomas D.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (04) : 263 - 270